SG Americas Securities LLC Invests $139,000 in Celcuity Inc. (NASDAQ:CELC)

SG Americas Securities LLC bought a new stake in Celcuity Inc. (NASDAQ:CELC) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 9,529 shares of the company’s stock, valued at approximately $139,000.

A number of other institutional investors and hedge funds also recently modified their holdings of CELC. Charles Schwab Investment Management Inc. raised its holdings in shares of Celcuity by 7.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 27,276 shares of the company’s stock valued at $256,000 after purchasing an additional 1,989 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Celcuity by 143.3% in the 1st quarter. Renaissance Technologies LLC now owns 74,356 shares of the company’s stock valued at $695,000 after purchasing an additional 43,800 shares during the period. State Street Corp raised its holdings in shares of Celcuity by 3.1% in the 1st quarter. State Street Corp now owns 148,802 shares of the company’s stock valued at $1,391,000 after purchasing an additional 4,466 shares during the period. Millennium Management LLC raised its holdings in shares of Celcuity by 50.4% in the 2nd quarter. Millennium Management LLC now owns 509,247 shares of the company’s stock valued at $4,634,000 after purchasing an additional 170,617 shares during the period. Finally, Citadel Advisors LLC bought a new stake in shares of Celcuity in the 2nd quarter valued at about $256,000. 63.33% of the stock is owned by institutional investors.

Celcuity Price Performance

Shares of Celcuity stock opened at $17.23 on Wednesday. Celcuity Inc. has a twelve month low of $8.39 and a twelve month high of $22.19. The company has a quick ratio of 13.43, a current ratio of 13.43 and a debt-to-equity ratio of 0.26. The company has a 50-day simple moving average of $17.47 and a two-hundred day simple moving average of $14.46. The stock has a market capitalization of $524.65 million, a price-to-earnings ratio of -6.41 and a beta of 0.78.

Wall Street Analysts Forecast Growth

CELC has been the topic of several research analyst reports. Needham & Company LLC restated a “buy” rating and set a $24.00 target price on shares of Celcuity in a research note on Friday, April 12th. HC Wainwright restated a “buy” rating and set a $27.00 price objective on shares of Celcuity in a research report on Thursday, March 28th. Stifel Nicolaus assumed coverage on Celcuity in a research report on Thursday, February 22nd. They issued a “buy” rating and a $40.00 target price on the stock. Finally, Craig Hallum increased their target price on Celcuity from $20.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, March 28th.

Celcuity Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.